SULFAPYRIDINE CALCIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C11H10N3O2S.Ca
Molecular Weight	536.64
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

[Ca++].NC1=CC=C(C=C1)S(=O)(=O)[N-]C2=CC=CC=N2.NC3=CC=C(C=C3)S(=O)(=O)[N-]C4=CC=CC=N4

InChI

InChIKey=YXZNOFHFTBDQKU-UHFFFAOYSA-N

InChI=1S/2C11H10N3O2S.Ca/c2*12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11;/h2*1-8H,12H2;/q2*-1;+2

HIDE SMILES / InChI

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C11H11N3O2S
Molecular Weight	249.289
Charge	0
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Sulfapyridine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. It was used to treat of infections in humans in particular, dermatitis herpetiformis (Duhring's disease), a skin problem, but that usage was discontinued by manufacturer. It is also known, that sulfapyridine is one of the two primary metabolite of the anti-inflammatory drug salicylazosulfapyridine.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial dihydropteroate synthase 44	Inhibitor 8,504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dermatitis herpetiformis 9	Curative		Approved 8,583	SULFAPYRIDINE

Doses

Show entries

Dose	Population	Adverse events
75 g multiple, oral	unhealthy, 32 years	Other AEs: Agranulocytosis...
30 g multiple, oral	unhealthy, 52 years	Other AEs: Purpura...
11 g multiple, oral	unhealthy, 72 years	Disc. AE: Anuria...
500 mg 2 times / day multiple, oral	unhealthy, 74.5 years (range: 53 - 86 years)	Disc. AE: Skin rash, Nausea... Other AEs: Headache, Urinary hesitancy...
4 g 1 times / day multiple, oral Highest studied dose	unhealthy, adult

Showing 1 to 5 of 5 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Agranulocytosis	grade 5, 1 patient	75 g multiple, oral	unhealthy, 32 years
Purpura	grade 5, 1 patient	30 g multiple, oral	unhealthy, 52 years
Anuria	grade 5, 1 patient Disc. AE	11 g multiple, oral	unhealthy, 72 years
Headache	1 patient	500 mg 2 times / day multiple, oral	unhealthy, 74.5 years (range: 53 - 86 years)
Urinary hesitancy	1 patient	500 mg 2 times / day multiple, oral	unhealthy, 74.5 years (range: 53 - 86 years)

Showing 1 to 5 of 8 entries

Previous1 2Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 2,438

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as perpetrator

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2C9 2,497	inhibitor 4,027	likely

Showing 1 to 1 of 1 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:132842	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:132842
ChemicalBook	CB8423160	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8423160
eMolecules	511929	https://www.emolecules.com/cgi-bin/more?vid=511929
MolPort	MolPort-000-883-306	https://www.molport.com/shop/molecule-link/MolPort-000-883-306
Selleck Chemicals	Sulfapyridine(Dagenan)	http://www.selleckchem.com/products/Sulfapyridine(Dagenan).html

Showing 1 to 5 of 6 entries

Previous1 2Next

PubMed

Show entries

Title	Date	PubMed
Evaluation of biotransformation of sulphasalazine in the colon epithelial Caco-2 cells.	2004 Dec	15909923
[Induction of tolerance in hypersensitivity to mesalazine (5-ASA)].	2005 Dec	16454598
[Qualification and quantification of 10 sulfonamides in animal feedstuff by high performance liquid chromatography-electrospray tandem mass spectrometry].	2005 Jul	16250451
Potential of nuclear quadrupole resonance in pharmaceutical analysis.	2005 Jul 1	15987093
Occurrence and sorption behavior of sulfonamides, macrolides, and trimethoprim in activated sludge treatment.	2005 Jun 1	15984773

Showing 1 to 5 of 50 entries

Previous1 2 3 4 5…10Next

Patents

Sample Use Guides

In Vivo Use Guide

For dermatitis herpetiformis: adults and adolescents: 250 milligrams to 1 gram four times a day until improvement occurs. After improvement has occurred, the dose should then be reduced by 250 to 500 milligrams every three days until there are no symptoms; that dose should be taken once daily. Children: use is not recommended, because children usually do not get this condition.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical
Record UNII	35HMH7A87O
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

SULFAPYRIDINE CALCIUM

Common Name

English

ORSULON

Preferred Name

English

BENZENESULFONAMIDE, 4-AMINO-N-2-PYRIDINYL-, CALCIUM SALT

Common Name

English

SULFANILAMIDE, N1-2-PYRIDYL-, CALCIUM SALT

Common Name

English

2-SULFANILAMIDOPYRIDINE CALCIUM SALT

Common Name

English

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

CAS

4374-96-3

PRIMARY

PUBCHEM

92135670

PRIMARY

CAS

6101-39-9

NON-SPECIFIC STOICHIOMETRY

FDA UNII

35HMH7A87O

PRIMARY

EPA CompTox

DTXSID00365545

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					Y5V2N1KE8U

Sulfapyridine

PARENT -> SALT/SOLVATE


					Y5V2N1KE8U

Sulfapyridine

PARENT -> SALT/SOLVATE

Amount:

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Related Record

Type

Details


					Y5V2N1KE8U

Sulfapyridine

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Sourcing

PubMed

Patents

Sample Use Guides

Drug as perpetrator